|Bid||0.0000 x 800|
|Ask||0.0000 x 1200|
|Day's Range||3.7000 - 4.2100|
|52 Week Range||1.6300 - 9.5600|
|Beta (5Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.50|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN) Akari Therapeutics PLC (NASDAQ: AKTX) Annexon Inc (NASDAQ: ANNX) Applied Molecular Transport Inc. (NASDAQ: AMTI) AxoGen, Inc (NASDAQ: AXGN) Burning Rock Biotech Ltd (NASDAQ: BNR) Celcuity Inc (NASDAQ: CELC) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Cerecor Inc (NASDAQ: CERC) Citius Pharmaceuticals Inc (NASDAQ: CTXR) DermTech Inc (NASDAQ: DMTK) Gemini Therapeutics Inc (NASDAQ: GMTX) Intra-Cellular Therapies Inc (NASDAQ: ITCI) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS) Mereo BioPharma Group plc – ADR (NASDAQ: MREO) Nantkwest Inc (NASDAQ: NK) Orthofix Medical Inc (NASDAQ: OFIX) PAVmed Inc (NASDAQ: PAVM) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS) Pliant Therapeutics Inc (NASDAQ: PLRX) RedHill Biopharma Ltd (NASDAQ: RDHL) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN) United Therapeutics Corporation (NASDAQ: UTHR) Vistagen Therapeutics Inc (NASDAQ: VTGN) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE) Pharming Group (NASDAQ: PHAR) Talis Biomedical Corp (NASDAQ: TLIS) Vallon Pharmaceuticals Inc (NASDAQ: VLON) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX) announced that Surface Oncology Inc (NASDAQ: SURF) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform. The antibody, SRF114, is a fully human IgG1 anti-CCR8 antibody that selectively depletes immuno-suppressive tumor T regulatory cells while sparing peripheral Tregs. The terms of agreement with Surface Oncology provided that Surface Oncology pay technology access and licensing fees in addition to research funding, and that Vaccinex will qualify for development milestone payments and royalties. In after-hours trading, Vaccinex shares were down 3.91% to $4.91, while Surface Oncology was up 12.33% to $10.20. Aridis to Study Inhaled Antibody Cocktail For Neutralizing Emerging Variants of The Novel Coronavirus Aridis Pharmaceuticals Inc (NASDAQ: ARDS) said it has augmented its inhaled AR-711 monoclonal antibody to COVID-19 with a second mAb, AR-713, that is designed to neutralize newly emerging COVID-19 mutated variants including those from South Africa, Brazil and Japan. Together, the enhanced dual antibody cocktail will be delivered as an inhaled treatment and is expected to provide broad coverage of all known high-risk strains, the company said. In addition, Aridis announced preclinical development services support from NIAID. The preclinical development services support is also provided by the Coronavirus Immunotherapy Consortium. Aridis said it is on track to initiate the program's Phase 1/2/3 clinical trial in second half of 2021. In premarket trading Tuesday, the stock was up 11:45% to $8.08. Celldex to Expand The Study of CDX-0159 For Additional Dermatologic Indication Celldex said it will expand clinical development of CDX-0159 into prurigo nodularis, a chronic skin disease characterized by the development of hard, intensely itchy nodules on the skin. CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. Frequency Therapeutics Announces Publication of Positive Phase 1/2 Study Data For Drug to Treat Hearing Loss Frequency Therapeutics Inc (NASDAQ: FREQ) announced the publication in Otology & Neurotology, results of its FX-322 Phase 1/2 study, showing hearing improvements in adults with acquired sensorineural hearing loss and the first-known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy. Findings from the Phase 1/2 study of FX-322, the company's lead product candidate to treat SNHL, showed statistically significant increases in word recognition and words-in-noise scores, the company added. View more earnings on IBB In after-hours trading, the stock was up 5.59% to $55. Related Link: The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings Revance's DaxibotulinumtoxinA Injection Shows Mixed Results In Mid-stage Study In Upper Limb Spasticity Revance Therapeutics Inc (NASDAQ: RVNC) announced topline data from its JUNIPER Phase 2 study of DaxibotulinumtoxinA for Injection for the treatment of adults with moderate to severe upper limb spasticity, showing mixed results. The company said the data validated efficacy and safety, while also achieving key co-primary endpoint on efficacy, with the 500-unit dose showing statistically significant difference from placebo in the Modified Ashworth Score improvement from baseline. On the Physician Global Impression Change assessment, all the three evaluated doses showed numerical improvement compared to placebo but did not reach statistical significance. Separately, the company reported a sharp increase in its fourth-quarter revenues to $11.1 million, with the increase primarily due to the commercial launch of the RHA Collection of dermal fillers and the HintMD fintech platform. The loss per share widened from 99 cents to $1.24, in line with the consensus. Protalix Reports Positive Late-stage Data For Drug to Treat Inherited Lysosomal Storage Disease Protalix Biotherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, announced positive topline results from the BRIGHT Phase 3 clinical trial evaluating pegunigalsidase alfa, 2 mg/kg, administered every four weeks, for the potential treatment of Fabry disease. PRX–102 is Protalix' cell-expressed recombinant, PEGylated, cross-linked α–galactosidase–A product candidate. The stock was climbing 10.64% to $5.72 in premarket trading Tuesday. Oncolytics Presents Pre-clinical Data Showing Synergistic Effect of Pelareorep Combination With CART T Cells In Treating Cancer Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced publication of an e-poster at the CAR-TCR Summit Europe 2021, which showed that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model, in stark contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. The stock was gaining 13.94% to $3.76 in premarket trading Tuesday. Earnings ImmuCell Corporation's (NASDAQ: ICCC) product sales rose modestly from $3.63 million in the fourth quarter of 2019 to $3.74 million in the fourth quarter of 2020. The company reversed to a profit of 3 cents from a loss of 4 cents, while analysts, on average, estimated a loss of 4 cents per share. The company also said it has recently submitted the last of five significant technical sections required to achieve FDA approval to market Re-Tain, its mastitis product under development. A response from the FDA to this chemistry, manufacturing and controls technical section is expected during the third quarter of 2021 after the statutory six-month review period. The stock declined 12.61% to $10.26 in after-hours trading. Offerings PAVmed said it's commencing an underwritten public offering of its common stock. All of the shares to be sold in the offering will be sold by the company, subject to customary closing conditions. PAVmed said it intends to use the net proceeds to repay all of its outstanding debt, including all outstanding convertible notes, with the balance to be used for working capital and general corporate purposes. The stock slipped 12.43% to $4.86 in after-hours trading. On The Radar Earnings Rubius Therapeutics Inc (NASDAQ: RUBY) (before the market open) Epizyme Inc (NASDAQ: EPZM) (before the market open) Clovis Oncology Inc (NASDAQ: CLVS) (before the market open) Epizyme Inc (NASDAQ: EPZM) (before the market open) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (after the close) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) (after the close) AtriCure Inc. (NASDAQ: ATRC) (after the close) Theravance Biopharma Inc (NASDAQ: TBPH) (after the close) Masimo Corporation (NASDAQ: MASI) (after the close) Insulet Corporation (NASDAQ: PODD) (after the close) Esperion Therapeutics Inc (NASDAQ: ESPR) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN) (after the close) Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the close) Inspire Medical Systems Inc (NYSE: INSP) (after the close) Penumbra Inc (NYSE: PEN) (after the close) Xencor Inc (NASDAQ: XNCR) (after the close) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the close) MacroGenics Inc (NASDAQ: MGNX) (after the close) Medtronic PLC(NYSE: MDT) (after the close) See more from BenzingaClick here for options trades from BenzingaThe Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of EarningsThe Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Antibody discovered via Vaccinex’s ActivMAb® Antibody Discovery PlatformROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Surface Oncology will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex’s ActivMAb® antibody discovery and novel viral display platform. The antibody, SRF114, is a fully human IgG1 anti-CCR8 antibody that selectively depletes immuno-suppressive tumor T regulatory cells (Tregs) while sparing peripheral Tregs. The terms of agreement with Surface Oncology provided that Surface Oncology pay technology access and licensing fees in addition to research funding, and that Vaccinex will qualify for development milestone payments and royalties. “We are thrilled to continue building on the recent success of our ActivMAb platform with the announcement of our licensing deal with Surface Oncology,” said Ernest Smith, chief scientific officer of Vaccinex. “The presence of Treg in human tumors is associated with resistance to immunotherapy and blocking CCR8 has been demonstrated to potentiate inhibition of tumor growth in animal studies. Data presented at SITC 2020 demonstrated that SRF114 specifically binds to human CCR8 and induces Treg destruction through antibody-dependent cellular cytotoxicity. We are pleased to have played a part in the development of this promising drug candidate and look forward to following continuing development of SRF114 and further interactions with Surface Oncology.” About ActivMAb®ActivMAb was developed by Vaccinex and is a proprietary mammalian cell-based antibody discovery and novel viral display platform. The technology has multiple applications, including discovery of antibodies specific for complex membrane antigens, discovery of antibodies with optimized developability, and protein optimization for expression and activity. Its novel capabilities enable selection of unique antibody drugs against difficult high-value targets, including multi-pass membrane proteins against which small molecule drugs have demonstrated low efficacy or high toxicity. About Vaccinex, Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. The company’s lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases. Beyond neurology, Vaccinex believes that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations. Forward Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about the expected timing and results of our ongoing and future clinical trials and our expectations regarding the potential benefits, activity and effectiveness of our product candidates. Forward-looking statements may involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, our history of operating losses and need to raise additional capital to continue as a going concern, risks related to our indebtedness, risks related to our dependence on our lead product candidate, pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our Form 10-K filed with the SEC on March 9, 2020 and subsequent periodic reports. Investor ContactJeremy FefferLifeSci Advisors, LLC212firstname.lastname@example.org Media ContactCait Williamson, Ph.D.LifeSci Communications, LLC646email@example.com
Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companies. The collaborations will focus on the use of Vaccinex's antibody discovery and novel viral display platform, ActivMAb, for antibody discovery. The names of the drug makers and the financial terms over the deals were not disclosed. The stock soared 119.9% in midday trading, making the stock the biggest gainer on major U.S. exchanges, even after paring an earlier gain of as much as 233.1%. Trading volume skyrocketed to 215.3 million shares, compared with the full-day average over the past 30 days of about 711,000 shares. Both the gain and the volume were the most for the stock since it went public in August 2018. It has now more than tripled (up 221.9%) over the past three months, while the iShares Nasdaq Biotechnology ETF has rallied 21.5% and the S&P 500 has gained 9.5%.